Where does novel antibiotics R&D stand among other pharmaceutical products: An industrial perspective?

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 5, 2008, Pages 551-552

  Tillotson, Glenn S ^a  

^a ViroPharma Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; DRUG APPROVAL; DRUG COST; DRUG FORMULARY; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL INFECTION; HUMAN; INFLUENZA; MEDICAL SOCIETY; MORTALITY; PNEUMONIA; PRESCRIPTION; RESPIRATORY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG INDUSTRY; HUMANS; RESEARCH;

EID: 55249127561     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.5.551     Document Type: Editorial

References (5)

1. Spellberg B, Guidos R, Gilbert D et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 155-164 (2008).
2. Projan SJ. Why is Big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427-430 (2003).
3. Falagas ME, Fragoulis KN, Karydis I. A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. PLoS ONE 20(1), e11 (2006).
4. Dellit TH, Owens RC, McGowan JE et al. Infectious Disease Society of America and Society of Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. 44, 159-177 (2007).
5. Price DB, Honeybourne D, Little P et al. Community-acquired pneumonia mortality: a potential link to antibiotic prescribing trends in general practice. Respir. Med. 98, 17-24 (2004).